Login / Signup

Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA.

Hiroki TanakaShinya HagiwaraDaiki ShiraneTakuma YamakawaYuka SatoChika MatsumotoKota IshizakiMiho HishinumaKatsuyuki ChidaKasumi SasakiEtsuo YonemochiKeisuke UedaKenjirou HigashiKunikazu MoribeTakashi TadokoroKatsumi MaenakaSakura TaneichiYuta NakaiKota TangeYu SakuraiHidetaka Akita
Published in: ACS nano (2023)
Based on the clinical success of an in vitro transcribed mRNA (IVT-mRNA) that is encapsulated in lipid nanoparticles (mRNA-LNPs), there is a growing demand by researchers to test whether their own biological findings might be applicable for use in mRNA-based therapeutics. However, the equipment and/or know-how required for manufacturing such nanoparticles is often inaccessible. To encourage more innovation in mRNA therapeutics, a simple method for preparing mRNA-LNPs is prerequisite. In this study, we report on a method for encapsulating IVT-mRNA into LNPs by rehydrating a Ready-to-Use empty freeze-dried LNP (LNPs(RtoU)) formulation with IVT-mRNA solution followed by heating. The resulting mRNA-LNPs(RtoU) had a similar intraparticle structure compared to the mRNA-LNPs prepared by conventional microfluidic mixing. In vivo genome editing, a promising application of these types of mRNA-LNPs, was accomplished using the LNPs(RtoU) containing co-encapsulated Cas9-mRNA and a small guide RNA.
Keyphrases
  • binding protein
  • crispr cas
  • genome editing
  • small molecule
  • single cell